{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26.6","upperLimit":"38.6","value":"31.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Amount of time following ABT-199 administration until \\>25% increase in serum IgM","dispersionType":"95% Confidence Interval","groups":[{"description":"ABT199 will be administered daily, with 28 consecutive days defined as a treatment cycle for a maximum for 26 cycles\n\nABT199: Oral BCL-2 antagonist","id":"OG000","title":"ABT199"}],"paramType":"MEDIAN","populationDescription":"1 participant was censored from the response analysis after it was determined that he had IgM Myeloma rather than Waldenstrom's macroglobulinemia.","reportingStatus":"POSTED","timeFrame":"4 years","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}